EXHIBIT 99.1


               VASO ACTIVE ENTERS INTO PRODUCT BROKERAGE AGREEMENT

DANVERS, Mass. - (BUSINESS WIRE) - July 26, 2005 - Vaso Active Pharmaceuticals,
Inc. (Vaso Active) (VAPH.pk) of Danvers, Massachusetts, announced today that the
Company entered into an exclusive brokerage agreement with Ferolie Corporation
d/b/a Eastern Sales & Marketing (ESM), of Montvale, New Jersey to sell all of
Vaso Active's products across all classes of retail trade in the Continental
United States. In addition, under the agreement, ESM will be Vaso Active's
non-exclusive agent to identify prospective licensees of its trademarks and
trade names. ESM is a full-service sales, marketing and merchandising agency
that provides comprehensive services for consumer packaged goods manufacturers
in various product categories, including food, drug, specialty and private
label. Major clients of ESM include Masterfoods (Uncle Ben's, KalKan and Mars),
Nestle Waters (Poland Spring), S.C. Johnson, Revlon, Twin Lab, and Turkey Hill.
ESM markets its clients' products in all classes of retail trade, including
grocery and drug chains (such as A&P, Pathmark and Duane Reade), as well as
specialty stores and mass merchandisers.

"This agreement marks a significant step forward for Vaso Active," said Joseph
Frattaroli, President of Vaso Active. "We are very pleased that ESM has agreed
to represent our products. ESM is an extremely strong sales and marketing
agency. We expect that this relationship will enhance our rollout strategy,"
said Frattaroli.

"We are very excited to be able to work with Vaso Active as they undertake the
broad distribution of their product line," said Tony Scudieri, President of
Ferolie. "Selling and marketing products effectively requires devotion beyond
the traditional every-day work commitment. Given the high quality, multi-product
pipeline offered by Vaso Active, as well the dedication of its management team,
I am confident this will be a seamless, efficient and profitable endeavor."

Forward-Looking Statements

Certain statements contained herein constitute "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are based on current expectations, estimates
and projections about the Company's industry, management's beliefs and certain
assumptions made by management. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are difficult to
predict. Because such statements involve risks and uncertainties, the actual
results and performance of the Company may differ materially from the results
expressed or implied by such forward-looking statements. Given these
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Unless otherwise required by law, the Company also
disclaims any obligation to update its view of any such risks or uncertainties
or to announce publicly the result of any revisions to the forward-looking
statements made here; however, readers should review carefully reports of
documents the Company files periodically with the SEC.

Contact:

Matt Carter
Vaso Active Pharmaceuticals, Inc.
978-750-1991 Ext. 28
mcarter@vasoactive.us